---
layout: default
title: Povidone
parent: Model Prediction Only (L5)
nav_order: 751
evidence_level: L5
indication_count: 1
---

# Povidone
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Povidone: From No Documented Original Indication to Congenital Ichthyosiform Erythroderma

## One-Sentence Summary

Povidone (PVP) is a synthetic water-soluble polymer. The record lists no original indication for it, but it is marketed in Canada in three over-the-counter-style products whose names suggest eye care.
The TxGNN model predicts it may be effective for **congenital ichthyosiform erythroderma**, a rare inherited skin disorder.
Currently **0 clinical trials** and **0 publications** support this prediction, so it rests on the model alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the record |
| Predicted New Indication | Congenital ichthyosiform erythroderma |
| TxGNN Prediction Score | 99.11% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 3 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Povidone is widely used as a pharmaceutical excipient, film-former and humectant. A topical barrier or hydration effect is conceivable in a disorder marked by impaired epidermal barrier function and scaling. This idea is speculative, and no trial, publication or pathway data in the record supports it.

The high TxGNN score (0.991) is a model output only. It may reflect connectivity in the knowledge graph rather than a true therapeutic signal, and no clinical data corroborates it.

DB11061 is povidone, not povidone-iodine. The antiseptic activity of iodine should therefore not be assumed to apply here.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2247538 | MURINE | Not listed | Not listed |
| 2301687 | CLEAR EYES TRIPLE ACTION RELIEF | Not listed | Not listed |
| 2344319 | ADVANCED RELIEF EYE DROPS | Not listed | Not listed |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has no supporting clinical trials or literature, no documented mechanism, and no usable safety data. A high model score alone is not enough to move this candidate forward.

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data, for example from DrugBank, to test whether a barrier or humectant effect is plausible in this disorder
- Approved indication text and dosage forms for the three DINs
- Literature and trial searches for povidone, or polymer-based topical emollients, in ichthyosis and related keratinisation disorders
- Confirmation that a topical route is available and suitable for the intended use
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

